Article Text

AB0203 Polyclonal Immunoglobulin Light Chains Levels in Elderly People with Rheumatoid Arthritis: Real Clinical Practice – The Influence of SDMARDs
  1. I.V. Pozharov1,
  2. Z.U. Mutovina1,
  3. A.D. Astakhova1,
  4. E.V. Ryazantseva1,
  5. A.V. Gordeev2
  1. 1Rheumatology, The Central Clinical Hospital of the Department for Presidential Affairs
  2. 2Rheumatology, Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation


Background Polyclonal immunoglobulin light chains (PLC) represent biomarkers of B cell activity in rheumatoid arthritis (RA) and are associated with increased mortality in general population. PLC levels appear to be elevated during preclinical and active periods of RA. Serum k and l light chains are important inflammatory indexes and may be used as indicators of disease activity in RA.

Objectives To explore association between serum PLC in cohorts of patients with RA depending on treatment and to determine whether PLC can be used as markers of treatment effectiveness.

Methods 150 patients with RA untreated and treated with sDMARDs were included in the study (n=52, n=98, respectively), and 31 patient with osteoarthritis. Approximately 75% of patients in all groups were elderly people. Serum levels of PLC were measured by immune nephelometry.

Results Median [lower and upper quartiles] polyclonal k and λ light chains serum concentrations in cohort of untreated RA patients were significantly higher in comparison with osteoarthritis and treated RA patients (κ: 3.1 [2.7; 3.6] vs 2.6 [2.1; 3.3] and 2.6 [2.3; 3.1] g/l, H=12.1, p<0,01; λ: 1.7 [1.3; 1.9] vs 1.4 [1.2; 1.8] and 1.3 [1.2; 1.7] g/l, p=0.014). Comparing groups treated with methotrexate, sulfasalazine and leflunomide (n=48, 15 and 16, respectively) showed no statistically significant difference of PLC levels. It appeared that treatment with methotrexate during at least 6 months reduced serum concentrations of PLC in patients with RA (κ untreated 3.0 [2.6; 3.4] vs κ methotrexate 2.6 [2.0; 2.8], p<0.01; λ untreated 1.8 [1.6; 2,05] vs λ methotrexate 1,4 [1.0; 1,7], p<0.01).

Conclusions PLC can be used as markers of treatment with sDMARDs effectiveness among elderly patients with multimorbidity.

  1. Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population. Mayo Clinic Proceedings. 2012;87(6):517–523. doi: 10.1016/j.mayocp.2012.03.009.

  2. Brebner JA, Stockley RA. Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Medicine Reports. 2013;5:4. doi:10.3410/M5-4.

  3. Deng X, Crowson CS, Rajkumar SV, Dispenzieri A, et al. Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis. J Rheumatol. 2015 Feb;42(2):181–7. doi: 10.3899/jrheum.140543.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.